Validation of the IMS CORE diabetes model

Value in Health

Volumn 17, Issue 6, 2014, Pages 714-724

  McEwan, Phil ^a,b   Foos, Volker ^c   Palmer, James L ^c   Lamotte, Mark ^c   Lloyd, Adam ^c   Grant, David ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^c IQVIA   (United States)

Author keywords

cost effectiveness; model; simulation; validation

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; SIMULATION; VALIDATION STUDY; COHORT ANALYSIS; DECISION SUPPORT SYSTEM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FOLLOW UP; HUMAN; PROSPECTIVE STUDY; TREATMENT OUTCOME;

COHORT STUDIES; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908120545     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.07.007     Document Type: Article

References (59)

1. Aguiree F, Brown A, Cho NH, et al. IDF Diabetes Atlas. 6th Edition. Available from: 〈http://www.idf.org/diabetesatlas〉. [Accessed August 12, 2014].
2. Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic Med 2012;29:855-62.
3. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl): S5-26.
4. Palmer JL, Beaudet A, White J, et al. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Adv Ther 2010;27:814-27.
5. Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness of detemirbased basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on metaanalysis results of four clinical trials. Curr Med Res Opin 2004;20:1729-46.
6. Palmer JL, Knudsen MS, Aagren M, et al. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. J Med Econ 2010;13:212-20.
7. Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14:357-66.
8. Valentine WJ, Tucker D, Silberman C, et al. Long-term costeffectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. Value Health 2009;12:1-9.
9. Palmer AJ, Roze S, Valentine WJ, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20(Suppl):S53-8.
10. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in US managed care formulary decisions: a private payer's experience. J Manag Care Pharm 2006;12:726.
11. Minshall ME, Roze S, Palmer AJ, et al. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clin Ther 2005;27:940-50.
12. Samyshkin Y, Guillermin A-L, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ 2012;15:6-13.
13. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl):1:S27-40.
14. Brown JB, Russell A, Chan W, et al. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000;50(Suppl):S15-46.
15. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: crosstesting two diabetes simulation models. Diab Res Clin Prac 2000;50(Suppl):S57-64.
16. Palmer AJ, Mount Hood 5 Modeling Group. Clarke P, Gray A, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health 2013;16:670-85.
17. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46.
18. Beaudet A, Clegg J, Thuresson P, et al. Review of utility values for economic modeling in type-2 diabetes. Value Health 2014;17:462-70.
19. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59.
20. Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33.
21. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
22. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81.
23. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
24. Caro JJ, Briggs AH, Siebert U, et al. Modeling Good Research Practices - overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32:667-77.
25. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Mak 2012;32:733-43.
26. Shyangdan D, Cummins E, Royle P, et al. Liraglutide for the treatment of type 2 diabetes. Health Technol Assess 2011;15(Suppl. 1):77-86.
27. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9.
28. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60 risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.
29. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006;29:1478-85.
30. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
31. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
32. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, et al., Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
33. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575.
34. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITIONEurope): a cluster-randomised trial. Lancet 2011;378:156-67.
35. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
36. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
37. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Nathan DM, Zinman B, et al., Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arc Intern Med 2009;169:1307.
38. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
39. Law AM, Kelton WD, Kelton WD. Simulation Modeling and Analysis. New York: McGraw-Hill, 1991.
40. van Dieren S, Beulens JWJ, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-9.
41. Kengne AP, Patel A, Marre M, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 2011;18:393-8.
42. Davis WA, Knuiman MW, Davis TME. An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. Intern Med J 2010;40:286-92.
43. Elley CR, Robinson E, Kenealy T, et al. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the New Zealand diabetes cohort study. Diabetes Care 2010;33:1347-52.
44. Cederholm J, Eeg-Olofsson K, Eliasson B, et al. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 2008;31:2038-43.
45. Yang X, So W-Y, Kong APS, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: The Hong Kong Diabetes Registry. Diabetes Care 2007;30:65-70.
46. Yang X, So W-Y, Kong APS, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 2008;101:596-601.
47. Donnan PT, Donnelly L, New JP, et al. Derivation and validation of a prediction score for major coronary heart disease events in a UK type 2 diabetic population. Diabetes Care 2006;29:1231-6.
48. Folsom AR, Chambless LE, Duncan BB, et al. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003;26:2777-84.
49. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
50. Tarride J-E, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 2010;28:255-77.
51. Van Dieren S, Peelen LM, Nöthlings U, et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011;54:264-70.
52. Simmons RK, Coleman RL, Price HC, et al. Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 2009;32:708-13.
53. Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study. Diabetologia 2010;53:821-31.
54. Chamnan P, Simmons RK, Sharp SJ, et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009;52:2001-14.
55. Del Prato S. Megatrials in type 2 diabetes: from excitement to frustration? Diabetologia 2009;52:1219-26.
56. Turing AM. Computing machinery and intelligence. Mind 1950;59:433-60.
57. McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9.
58. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551.
59. McEwan P, Bergenheim K, Yuan Y, et al. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics 2010;28:665-74.